Loading... Please wait...
Sort by:

 

firstview-jpg.jpgFirstView reports deliver unique insight into current and future pharma market dynamics through quantitative surveys with physicians. With the ability to query a 1-million strong online physician community worldwide, FirstView provides essential data to support effective decision making in major disease areas and on key industry issues.

  • Market Access Impact: Asthma/COPD (US) 2016
    Learn More Market Access Impact: Asthma/COPD (US) 2016
    Are market barriers helping or hindering your asthma/COPD brand’s performance? Three brands top the list in the US as the most prescribed treatments for asthma and COPD, but are these the preferred options or are...
  • Medical Affairs Reputations T2DM (EU5)
    Learn More Medical Affairs Reputations T2DM (EU5)
    Fierce competition in T2DM medical affairs. Can the top two teams hold onto their lead? Two medical affairs teams lead in the EU5 type 2 diabetes mellitus (T2DM) market, but for how long? Competition is fierce, and a...
  • Medical Affairs Reputations T2DM (US)
    Learn More Medical Affairs Reputations T2DM (US)
    Two medical affairs teams are way ahead. Can your team learn from their success? Two medical affairs teams have taken a big lead in the US type 2 diabetes mellitus (T2DM) market. Are they delivering the services doctors...
  • Medical Affairs Reputations: Melanoma (EU5)
    Learn More Medical Affairs Reputations: Melanoma (EU5)
    Top marks from oncologists show medical affairs push is paying off for immunotherapies In the EU5 Melanoma treatment market, one brand’s medical affairs team is reaching more oncologists—and earning...
  • Medical Affairs Reputations: Melanoma (US)
    Learn More Medical Affairs Reputations: Melanoma (US)
    Top marks from oncologists show medical affairs push is paying off for immunotherapies In the EU5 Melanoma treatment market, one brand’s medical affairs team is reaching more oncologists—and earning...
  • Medical Affairs Reputations: Multiple Sclerosis (US)
    Learn More Medical Affairs Reputations: Multiple Sclerosis (US)
    MS medical affairs: oral therapies outperforming in the US. How does your team measure up? In the US multiple sclerosis (MS) market, medical affairs teams for oral therapies outperform their platform-therapy...
  • Medical Affairs Reputations: Multiple Sclerosis (EU5)
    Learn More Medical Affairs Reputations: Multiple Sclerosis (EU5)
    MS medical affairs: oral therapies outperforming in Europe. How does your team measure up? In Europe’s Multiple Sclerosis (MS) market, medical affairs teams for oral therapies outperform their platform-therapy...
  • Market Access Impact: Growth Hormone Deficiency (EU5)
    Learn More Market Access Impact: Growth Hormone Deficiency (EU5)
    GHD: Has one brand found the winning market access strategy in Europe? Market barriers affect nearly 25% of growth hormone prescriptions in Europe, costing most brands market share. But one brand’s efforts to...
  • Market Access Impact: Growth Hormone Deficiency (US)
    Learn More Market Access Impact: Growth Hormone Deficiency (US)
    GHD: Has one brand found the winning market access strategy in the US? Market barriers affect nearly 40% of growth hormone prescriptions in the US, and most brands lose market share because of them. But one brand has...
  • Medical Affairs Reputations: HIV (US)
    Learn More Medical Affairs Reputations: HIV (US)
    HIV: Hard work is paying off for the top 2 medical affairs teams in the US. How is your team doing? In the past 6 months, the medical affairs teams for two leading HIV treatments reached more doctors than any other...
  • Medical Affairs Reputations: HIV (EU5)
    Learn More Medical Affairs Reputations: HIV (EU5)
    HIV: Hard work is paying off for the top 2 medical affairs teams in Europe. How is your team doing? In the past 6 months, the medical affairs teams for two leading HIV treatments reached up to 91% of the doctors we...
  • Market Access Impact: Renal Cell Carcinoma (EU5)
    Learn More Market Access Impact: Renal Cell Carcinoma (EU5)
    Market barriers cause net share loss for 5 major RCC treatments in Europe. Is your brand one of them? We researched 8 renal cell carcinoma (RCC) treatments to see what happens to their share of the European market when...
  • Market Access Impact: Renal Cell Carcinoma (US)
    Learn More Market Access Impact: Renal Cell Carcinoma (US)
    Market barriers boost net share for 6 major RCC treatments in US. Is your brand one of them? We researched 9 renal cell carcinoma (RCC) treatments to see what happens to their share of the US market when oncologists...
  • Medical Affairs Reputations: Renal Cell Carcinoma (US)
    Learn More Medical Affairs Reputations: Renal Cell Carcinoma (US)
    Opdivo’s medical affairs team working overtime to engage oncologists. Is it paying off? Opdivo’s medical affairs team has been busy. Since late 2015, when the Anti-PD-1 monoclonal antibody got FDA approval...
  • Medical Affairs Reputations: Renal Cell Carcinoma (EU5)
    Learn More Medical Affairs Reputations: Renal Cell Carcinoma (EU5)
    4 medical affairs teams working hard to engage oncologists. Which one gets top marks?  European medical affairs teams for four renal cell carcinoma (RCC) treatments have been working overtime, interacting with...
  • Market Access Impact: HIV (US)
    Learn More Market Access Impact: HIV (US)
    Can prescription barriers help other HIV brands catch up to the runaway market leader? In the US HIV treatment market, the #1 brand has a 10% market share lead over its nearest rival. Will market barriers be the...

customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved